Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study
Issued Date
2025-02-01
Resource Type
ISSN
18760341
eISSN
1876035X
Scopus ID
2-s2.0-85214306753
Journal Title
Journal of Infection and Public Health
Volume
18
Issue
2
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infection and Public Health Vol.18 No.2 (2025)
Suggested Citation
Setpakdee R., Kiertiburanakul S. Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study. Journal of Infection and Public Health Vol.18 No.2 (2025). doi:10.1016/j.jiph.2024.102630 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102714
Title
Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: There are limited data on DTG-associated weight gain among treatment-naïve Asian people living with HIV (PLHIV). Methods: Eighty-one and 100 PLHIV initiating DTG-based and efavirenz (EFV)-based antiretroviral therapy (ART), respectively, were retrospectively investigated for weight changes and lipid profiles at 6 and 12 months after ART initiation. Results: At baseline, the DTG group had a lower mean body weight (BW) (60.7 kg vs. 64.3 kg, p = 0.071) and lower mean cholesterol level (172 mg/dL vs. 185 mg/dL, p = 0.029) than the EFV group. Mean BW remained lower in the DTG group than in the EFV group at 6 [58.2 kg vs. 66.0 kg, mean difference (MD) −7.8, p = 0.005] and 12 (59.6 kg vs. 67.0 kg, MD −7.3, p = 0.008) months. BW did not significantly change between baseline and 12 months in the DTG group (60.7 kg vs. 59.6 kg, p = 0.495), whereas it significantly increased between baseline and 12 months in the EFV group (64.3 kg vs. 66.9 kg, p = 0.019). Cholesterol levels did not significantly increase between baseline and 12 months in either group. After adjustment, DTG use [MD −5.85, 95 % confidence interval (CI) −10.45, −1.24, p = 0.013] and baseline BW (MD 0.97, 95 % CI 0.79, 1.15, p < 0.001) were significantly associated with BW changes over time. Conclusions: DTG-based ART was not significantly associated with increased BW and cholesterol levels compared with EFV-based ART in treatment-naïve Thai PLHIV.